Text size Walgreens continues to benefit from administering vaccines for Covid-19. Joe Raedle/Getty Images Walgreens Boots Alliance reported higher earnings than Wall Street expected and raised its financial forecast for the year, but it wasn’t enough to keep the stock in positive territory. Walgreens Boots Alliance (ticker: WBA) shares were up 2.2% in the early
Walgreens Boots Alliance
reported higher earnings than Wall Street expected and raised its financial forecast for the year, but it wasn’t enough to keep the stock in positive territory.
Walgreens Boots Alliance
(ticker: WBA) shares were up 2.2% in the early premarket hours, before falling back for a loss of 6.7% as regular trading began. Shares are up about 23% so far this year.
The stock is making a spectacular comeback in 2021. Walgreens shares fell 32.4% last year, making it the second-worst performer in the
Dow Jones Industrial Average.
This year, it was the third best, behind
Goldman Sachs Group
(AXP), as of the close of trading on Wednesday.
In its earnings report Thursday morning, the company said it now expects 10% growth in adjusted per-share earnings from continuing operations in 2021. That is up from its last earnings report, when it said it expected “mid-to-high single digit growth.”
The Wall Street consensus sees Walgreens earnings falling 1.1% from last year’s levels, according to FactSet.
Walgreens reported adjusted earnings for the third quarter of its fiscal year of $1.51 per share, beating the FactSet consensus estimate of $1.16 per share. The company reported sales of $34 billion, above the FactSet consensus estimate of $33.5 billion.
In a note out early Thursday, Guggenheim analyst Glen Santangelo wrote that the results are in line with the easing of pandemic-era restrictions. “The company’s operations seem to be benefiting consistent with the reopening,” Santangelo wrote. “We believe the results are strong enough to support the shares today, but we appreciate investors are still looking to better understand how the new CEO’s long-term strategy may differ from previous management.”
The company’s CEO,
succeeded former CEO
Walgreens said that U.S. sales were $28.7 billion for the quarter, up 5.1% from the same quarter last year. It said that the company has administered more than 25 million Covid-19 vaccines so far, and that Walgreens had administered 8 million Covid-19 tests, while Boots had administered 3 million.
The company attributed its improved earnings outlook in part to the Covid-19 vaccinations it is administering. “The revised guidance reflects strong results in the third quarter and greater clarity on the impact of COVID-19 vaccinations,” the company said.
In his note on the earnings report, Guggenheim’s Santangelo wrote that the company’s balance sheet is better than it was before it sold its Alliance Healthcare business to
(ABC), a $6.5 billion transaction that closed in June.
“Given the longterm structural challenges to the retail pharmacy business, we believe investors may take a wait and see approach on the stock until the strategy becomes more transparent,” Santangelo wrote.
Santangelo rates the stock a Buy. Of the 21 analysts tracked by FactSet who cover Walgreens, only two rate it Buy or Overweight, while 17 rate it a Hold and two rate it Sell or Underweight.
Write to Josh Nathan-Kazis at [email protected]